Advisory - Several children's strawberry-flavoured acetaminophen syrups recalled because of defective child-resistant safety caps on the bottles
OTTAWA, Nov. 14, 2018 /CNW/ -
Issue Laboratoire Riva Inc. and Laboratoires Trianon Inc. are voluntarily recalling several over-the-counter children's strawberry-flavoured acetaminophen syrups labeled as Biomedic, Option+, or Laboratoires Trianon Inc. The products, which are used for pain and fever relief, are being recalled because the child-resistant safety cap may be defective.
A defective cap could allow a child to accidentally ingest the product, which would pose a significant health concern. Accidental ingestion can result in acetaminophen overdose and serious health consequences, including liver damage in extreme cases. Early signs of overdose include nausea, vomiting, lethargy and sweating. Liver damage may result in liver failure or death. Abdominal pain may be the first sign of liver damage and may not be apparent for 24 to 48 hours.
This issue is related to product packaging and not the safety or effectiveness of the drug in the bottles. The products were distributed at major pharmacies across Canada.
Who is affected
Consumers who have bought the affected products listed in the table below
Return affected product to the place of purchase for a refund.
Call your local poison control centre immediately if you think your child may have taken too much acetaminophen. Consult your health care professional if your child has used these products and has health concerns.
Contact Urszula Wiatrowska, Pharmacovigilance Specialist at Laboratoire Riva and Laboratoires Trianon Inc., if you have questions about the recall. Email [email protected], or call toll-free at 1-800-363-7988, extension 236.
Store medications out of reach and sight of children.
What Health Canada is doing Health Canada is monitoring the recalls. Should additional safety concerns be identified related to this issue, Health Canada will take appropriate action and inform Canadians as necessary.
Stay connected with Health Canada and receive the latest advisories and product recalls.
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to ResearchAndMarkets.com's offering.
Infectious disease Dx is...